Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strong Phase III Data Have Linaclotide On Track For Filing In 2011

Executive Summary

Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.

You may also be interested in...



Ironwood Adds A China Wrinkle To Regional Deal Strategy

The December US launch of linaclotide is a transformative event for Ironwood Pharmaceuticals, the GI drug’s discoverer. But the company’s recent deal with AstraZeneca to sell the drug in China represents another kind of feat and highlights the growing importance of regional deals to Western biotechs.

Ironwood Eyes Large Market For Linaclotide, Will Tread Carefully On Price

Ironwood Pharmaceuticals Inc. is confident about the large market potential for its constipation drug linaclotide, but as the market now is dominated by over-the-counter laxatives, it knows it has to be "smart" when it comes to price in order to win over payers.

Ironwood Eyes Large Market For Linaclotide, Will Tread Carefully On Price

Ironwood Pharmaceuticals Inc. is confident about the large market potential for its constipation drug linaclotide, but as the market now is dominated by over-the-counter laxatives, it knows it has to be "smart" when it comes to price in order to win over payers.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS052636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel